ReviewFrontiers in immunology2026
Integrated airway epithelial signaling networks linking allergen-driven inflammation to airway remodeling in asthma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic inflammatory airway disease characterized by persistent immune activation, airway hyperresponsiveness, and progressive structural remodeling. The airway epithelium functions as the primary sensor of inhaled allergens and actively orchestrates both innate and adaptive immune responses through alarmin and chemokine release, while directly driving structural changes via epithelial-mesenchymal transition and profibrotic mediator production. Upon allergen challenge, exemplified by house dust mite, airway epithelial cells activate an integrated network of signaling pathways, including epidermal growth factor receptor, mitogen-activated protein kinase, PI3K/protein kinase B, nuclear factor kappa B (NF-κB), Janus kinase/signal transducer and activator of transcription (STAT), and transforming growth factor-β/SMAD, which converge on key transcription factors, including NF-κB/RelA, AP-1, STAT6, SMAD2/3, and CCAAT/enhancer-binding protein beta, to coordinately induce the production of acute inflammatory factors, including alarmins (thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, IL-25), and chemokines (C-C motif chemokine ligand 20, C-X-C motif chemokine ligand 8), as well as chronic cellular remodeling, including goblet cell hyperplasia, subepithelial fibrosis, and smooth muscle expansion. This review provides a comprehensive, network-centered synthesis of these mechanisms, with a particular focus on the molecular basis of asthma endotype heterogeneity, amplifying role of viral exacerbations, epigenetic regulation of epithelial inflammatory programs, and signaling basis of corticosteroid resistance. Further, we map the mechanistic basis of the phenotypic heterogeneity across eosinophilic, neutrophilic, and mixed asthma endotypes onto specific network configurations and then discuss therapeutic implications spanning approved biologics, kinase inhibitors, barrier-restoration strategies, and combinatorial approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.